Layoff

Quote

Anonymous

Guest
This is all correct, - Good Luck:


Neuro getting in licensing of 2 new drugs...most will be safe

Msk- cuts...about. 30%

Cardio- cuts about 40%

Diabetes- cuts around 50%

Men's health-cuts around 15%

In all cases fde gone first. But the best will be hired back for open territories. No vep....severance will be 3 months. Cuts to fte based upon tenure and location...tie breaker is past reviews last 3 years. Associates inside looking t get out in field will be waiting long time- no dsm jobs as cuts there also. District size going to 15-20 direct reports multiple states in most cases. Managers will lose jobs

Hold on going to be rough ride...pipeline not delivering at all. Company looking for neuro to save company as highest. Roi reps resided there. Management high on neuro reps...feels cardio reps way under perform. In licensing agreement to be announced soon..both drugs potential to hit 500 million with right sales force. Avg raise this year will be under 2%.

Best of luck in sales going to get real toy with higher expectations and more pip for non performers.
 






Whatever it takes to bump up the stock price.
Anonymous said:
This is all correct, - Good Luck:


Neuro getting in licensing of 2 new drugs...most will be safe

Msk- cuts...about. 30%

Cardio- cuts about 40%

Diabetes- cuts around 50%

Men's health-cuts around 15%

In all cases fde gone first. But the best will be hired back for open territories. No vep....severance will be 3 months. Cuts to fte based upon tenure and location...tie breaker is past reviews last 3 years. Associates inside looking t get out in field will be waiting long time- no dsm jobs as cuts there also. District size going to 15-20 direct reports multiple states in most cases. Managers will lose jobs

Hold on going to be rough ride...pipeline not delivering at all. Company looking for neuro to save company as highest. Roi reps resided there. Management high on neuro reps...feels cardio reps way under perform. In licensing agreement to be announced soon..both drugs potential to hit 500 million with right sales force. Avg raise this year will be under 2%.

Best of luck in sales going to get real toy with higher expectations and more pip for non performers.
Click to expand...
 






Anonymous said:
This is all correct, - Good Luck:


Neuro getting in licensing of 2 new drugs...most will be safe

Msk- cuts...about. 30%

Cardio- cuts about 40%

Diabetes- cuts around 50%

Men's health-cuts around 15%

In all cases fde gone first. But the best will be hired back for open territories. No vep....severance will be 3 months. Cuts to fte based upon tenure and location...tie breaker is past reviews last 3 years. Associates inside looking t get out in field will be waiting long time- no dsm jobs as cuts there also. District size going to 15-20 direct reports multiple states in most cases. Managers will lose jobs

Hold on going to be rough ride...pipeline not delivering at all. Company looking for neuro to save company as highest. Roi reps resided there. Management high on neuro reps...feels cardio reps way under perform. In licensing agreement to be announced soon..both drugs potential to hit 500 million with right sales force. Avg raise this year will be under 2%.

Best of luck in sales going to get real toy with higher expectations and more pip for non performers.
Click to expand...
I say no way. Did you listen to John's call? We do not have any in licensing going on. We are waiting for our pipeline and that looks great for diabetes and oncology. Autoimmune drugs are great but need very few reps because it is so specialized and will go to the Forteo group. NERI is out last hope for many in Biomedicines.
 






Anonymous said:
I say no way. Did you listen to John's call? We do not have any in licensing going on. We are waiting for our pipeline and that looks great for diabetes and oncology. Autoimmune drugs are great but need very few reps because it is so specialized and will go to the Forteo group. NERI is out last hope for many in Biomedicines.
Click to expand...

Agree with this post... I'm not sure how he stated we were committed to Neuroscience?!?! Other than NERI( data looks sketchy) what's in the pipeline? Even if Sola will be successful, another trial is needed and that will take YEARS?! Doubtful the FDA will aporove a drug that failed primary endpoints but pooled data was hopeful?! He said LLY is the only company committed to NS( are we really?!?!). That's because others realize it's not worth investing in molecules that aren't making it to market. I don't think NS will make it- Biomedicines must go through a major transformation starting with sr leaders(many should go) then consolidate sales forces- duplication of efforts is killing the industry and not generating greater $$$.
 






We are committed to Neuroscience if you look at the longgggg term pipeline. We are talking 10-15 years. This will not save all of the jobs in BIOmedicines. Basically the primary care/men's health reps have the next couple of years with Cialis and Axiron. We still need reps on Effient and Strattera but the number of reps is the big question.
 












Just wait until National Health Care starts really taking a grip. Pharm jobs are the way of the past. Govt will control what meds will be dispersed to patients. Branded products gone. Why can't you bafoons see the writing on the wall?
 






Anonymous said:
Just wait until National Health Care starts really taking a grip. Pharm jobs are the way of the past. Govt will control what meds will be dispersed to patients. Branded products gone. Why can't you bafoons see the writing on the wall?
Click to expand...

Okay, wise guy.

Why was Prozac so glorious in the 90s but not when the patent ended?
 






The answer is that when Prozac went generic, there were no more Prozac samples flooding into doctor's offices. There were still samples many other branded drugs for depression in the sample closet when Prozac lost the patent, so the doctor just chose to use those to start patients.
 






Top Bottom
Back
Quote